RA
TVTX icon

Royce & Associates’s Travere Therapeutics TVTX Stock Holding History

Royce & Associates’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-123,250
Closed -$2.95M – 814
2025
Q3 		$2.95M Sell
123,250
-257,747
-68% -$4.85M 0.03% 549
2025
Q2 		$5.64M Buy
+380,997
New +$6.32M 0.06% 433
2024
Q3 		– Sell
-47,573
Closed -$391K – 909
2024
Q2 		$391K Hold
47,573
– – ﹤0.01% 806
2024
Q1 		$367K Buy
47,573
+5,932
+14% +$50K ﹤0.01% 809
2023
Q4 		$374K Buy
41,641
+23,302
+127% +$170K ﹤0.01% 808
2023
Q3 		$164K Buy
+18,339
New +$259K ﹤0.01% 884

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royce & Associates's TVTX Position: Q4 2025 in Review

Royce & Associates sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 123,250 shares — an estimated $2.95M sold.

Royce & Associates first reported a position in TVTX in Q3 2023 and held it in 6 quarters. The position peaked at $5.64M in Q2 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Royce & Associates reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Royce & Associates sold 123,250 Travere Therapeutics shares in Q4 2025, an estimated $2.95M.
  • Royce & Associates first reported a position in Travere Therapeutics in Q3 2023 and held it in 6 quarters.
  • Royce & Associates's Travere Therapeutics position peaked at $5.64M in Q2 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Royce & Associates's 13F filing for Q4 2025, filed 9 Feb 2026.